Lundbeck and Takeda take on Lupin over anti-depressant ANDA

Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Lundbeck to acquire Abide Therapeutics for $250 million

8 May 2019 Danish pharmaceutical company Lundbeck will acquire Abide Therapeutics, it has been announced.

Americas

Takeda and Lundbeck take more patent action over Trintellix

12 June 2018 Drug makers Takeda and Lundbeck have filed a patent infringement lawsuit over anti-depressant medication Trintellix (vortioxetine hydrobromide), less than a month after launching similar claims.

Asia-Pacific

Takeda makes fourth offer to buy Shire

23 April 2018 Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Lundbeck and Takeda take on Lupin over anti-depressant ANDA

More on this story

Editor's picks

Editor's picks

More features